ANTI-GB3 ANTIBODIES USEFUL IN TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention lies in the field of new cancer therapies, more precisely in the field of antiangiogenic compounds. It notably concerns anti-Gb3 antibodies having specific CDR sequences, as well as the use of anti-Gb3 antibodies not coupled to a therapeutic molecule in the treatment of diseases associated with angiogenesis, such as solid tumors.
5 Citations
43 Claims
-
1-21. -21. (canceled)
-
22. An antibody directed against the membrane glycosphingolipid globotriaosylceramide (Gb3), or a functional fragment or a derivative thereof, characterized in that it has at least one complementarity determining region (CDR) with an amino acid sequence selected from SEQ ID NO:
- 1 to 42, or with an amino acid sequence having at least 80% identity with one of SEQ ID NO;
1 to 42. - View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 43)
- 1 to 42, or with an amino acid sequence having at least 80% identity with one of SEQ ID NO;
- 38. A method for treating a disease associated with angiogenesis in a subject in need thereof, comprising the administration of an effective quantity of an antibody directed against the membrane glycosphingolipid Gb3 and not coupled to a therapeutic molecule.
-
42. A method to inhibit angiogenesis in a subject in need thereof, comprising the administration of an effective quantity of an antibody directed against the membrane glycosphingolipid Gb3 and not coupled to a therapeutic molecule.
Specification